March 30th 2023
In honor of Women's History Month, Beth Prairie, MD, MPH, chief medical officer, West Penn Hospital, shares her experience as a female in medicine and as a woman in leadership.
March 14th 2023
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
6th Annual Advanced Practice Collaborative
4th Annual International Congress on the Future of Women’s Health™
22nd Annual International Congress on the Future of Breast Cancer® East
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
Clinical Conversations With the Cancer Care Team: Discussing the Impact of Social Inequities on Treatment Outcomes in Triple-Negative Breast Cancer
Focusing on Fabry Disease in Females: Individualizing Diagnostic and Counseling Plans to Improve Long-Term Outcomes
Neurodevelopmental disorders from in utero COVID-19 exposure based on sexMarch 28th 2023
In a recent study, female offspring of mothers with a positive COVID-19 test during pregnancy were at a decreased risk of developing neurodevelopmental disorders compared to male offspring.
Best practices for well woman visits for the adolescent patientMarch 28th 2023
Millicent McCarren, MD, of Allegheny Health Network, sits down with Contemporary OB/GYN® to discuss tips, tricks, and clinical pearls for making sure your adolescent patients are coming in for their routine well woman visits.
Managing hyperglycemia in hospitalized adultsMarch 27th 2023
The 2012 Management of Hyperglycemia in Hospitalized Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline was recently reviewed by a panel of clinician experts for use in adults hospitalized with hyperglycemia.
Relugolix combination therapy effective against symptomatic uterine fibroidsMarch 24th 2023
In a recent study, women with symptomatic uterine fibroids saw reduced symptom burden and improved quality of life after 24 weeks of treatment through relugolix combination therapy.
FDA gives clearance and CLIA waiver to second generation sexual health testMarch 21st 2023
Visby Medical has announced its second generation point of care test for detecting sexually transmitted diseases in women has received 510(k) clearance and a CLIA waiver from the FDA.